logo-loader
viewMindMed Inc.

MindMed takes another step forward adding MDMA to their R&D pipeline

MindMed (OTCQB: MMEDF) CO-CEO Jr Rahn joined Steve Darling from Proactive to announce the company has now added MDMA to its research and development pipeline.

Rahn telling Proactive about some of the clinical studies they are doing including a new one called Project Lucy.

Quick facts: MindMed Inc.

Price: 0.3299 USD

OTCQB:MMEDF
Market: OTCQB
Market Cap: $65.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MindMed Inc. named herein, including the promotion by the Company of MindMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MindMed investigating potential benefits of DMT in upcoming Phase 1 clinical...

Mind Medicine Inc (NEO:MMED) (OTCQB:MMEDF) CEO JR Rahn tells Proactive it is pursuing research into DMT, the active ingredient in Ayahuasca. Rahn says its part of a research and development collaboration that the psychedelics company has with the University Hospital Basel’s Liechti Lab....

3 weeks, 2 days ago

2 min read